Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
691 stopped studies mapped to Malignant Head and Neck Neoplasm and descendants · 92% state a reason
Over the 691 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT01967927 | Understanding GRID Radiation Therapy Effects on Human Tumor Oxygenation and Interstitial… | Early Phase 1 | withdrawn | Oct 23, 2013 | University of Arkansas | Study has been open for 8 years with no enrollment. Procedures in 2013 protocol are outdated.… | Enrollment / accrual |
| NCT03630120 | Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer | Phase 2 | terminated | Aug 14, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Lack of efficacy | Efficacy / futility |
| NCT03682367 | Perioperative Analgesia Using Gabapentin in Head and Neck Cancer Surgery | Phase 3 | terminated | Sep 24, 2018 | University of California, Davis | Poor Recruitment | Enrollment / accrual |
| NCT03938337 | Abemaciclib and Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer | Phase 2 | terminated | May 6, 2019 | University of Alabama at Birmingham | Sponsor terminated study due to higher incidence of pulmonary toxicity than expected, including… | Safety / toxicity |
| NCT03463889 | Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid… | Phase 2 | terminated | Mar 13, 2018 | University of California, San Francisco | Funding | Funding |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in…(ADHERE) | Phase 3 | withdrawn | Sep 17, 2018 | European Organisation for Research and Treatment of Cancer - EORTC | Company withdrew interest | Sponsor / business decision |
| NCT01126216 | Reduced Radiotherapy With Pac/Cis vs Standard Radiotherapy With 5-FU/Cis in Locally…(Paccis-RCT) | Phase 3 | terminated | May 19, 2010 | University of Erlangen-Nürnberg Medical School | After an Interims analysis the Data Safety Monitoring board recommended this because no significant… | Safety / toxicity |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2… | Phase 2 | withdrawn | Jan 4, 2018 | The University of Hong Kong | Sponsor withdrew funding for Nivolumab | Funding |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | Phase 1 | withdrawn | Jun 27, 2007 | University of Maryland, Baltimore | major amendments in progress | Other (stated, no rule matched) |
| NCT02177838 | Cetuximab and Radiation Therapy in Treating Patients With Stage III-IV Head and Neck… | N/A | terminated | Jun 30, 2014 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT04268329 | Evaluating the Use of an Informational Head and Neck Cancer Website. | N/A | terminated | Feb 13, 2020 | University of Illinois at Chicago | The study was not providing useful information. | Other (stated, no rule matched) |
| NCT03729297 | Cabozantinib in Advanced Salivary Gland Cancer Patients(Cabo ASAP) | Phase 2 | terminated | Nov 2, 2018 | Radboud University Medical Center | safety issues | Safety / toxicity |
| NCT00904345 | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck… | Phase 2 | terminated | May 19, 2009 | University of Michigan Rogel Cancer Center | Stopped early for funding and efficacy reasons. | Efficacy / futility |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid… | N/A | withdrawn | Oct 15, 2012 | Medstar Health Research Institute | not stated | Not stated |
| NCT04041141 | Oral Stent Device for Radiation Treatments of Oral Cancers | — | withdrawn | Aug 1, 2019 | Indiana University | replaced with other study | Other (stated, no rule matched) |
| NCT03887442 | Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma…(EXTAX) | Phase 2 | terminated | Mar 25, 2019 | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello | low recruitment rate | Enrollment / accrual |
| NCT03818542 | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly… | Phase 1 | terminated | Jan 28, 2019 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT01602315 | A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck… | Phase 1 / Phase 2 | terminated | May 18, 2012 | Novartis Pharmaceuticals | early termination due to Sponsor decision (slow recruitment) | Enrollment / accrual |
| NCT03246854 | A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | Phase 1 | terminated | Aug 11, 2017 | National Health Research Institutes, Taiwan | No more funding | Funding |
| NCT03655444 | Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell… | Phase 1 / Phase 2 | terminated | Aug 31, 2018 | Washington University School of Medicine | Provider of drug decided to discontinue study. | Other (stated, no rule matched) |
| NCT02946918 | Levothyroxine Replacement With Liquid Gel Capsules vs Tablets Post-thyroidectomy | Phase 4 | terminated | Oct 27, 2016 | University of Texas Southwestern Medical Center | Terminating study as sponsor has sold the drug to another company | Sponsor / business decision |
| NCT00011492 | Patient Evaluation for Head and Neck Surgery Branch Studies | — | terminated | Feb 23, 2001 | National Institute on Deafness and Other Communication Disorders (NIDCD) | Closed by Sponsor/Data Safety monitoring Board/IRB | Safety / toxicity |
| NCT04262388 | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab…(DOME) | Phase 2 | withdrawn | Feb 10, 2020 | University Health Network, Toronto | Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does… | Other (stated, no rule matched) |
| NCT03479463 | Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/Pharyngectomy | — | terminated | Mar 27, 2018 | MiMedx Group, Inc. | Slow enrollment | Enrollment / accrual |
| NCT03065634 | Return to Work and Living Healthy After Head and Neck Cancer(RELIANCE) | N/A | terminated | Feb 28, 2017 | University of Leipzig | insufficient recruitment rate | Enrollment / accrual |
| NCT04231864 | Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic… | Phase 2 | withdrawn | Jan 18, 2020 | Alain Algazi | Feasibility | Other (stated, no rule matched) |
| NCT02012231 | Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in… | Phase 1 | terminated | Dec 16, 2013 | Fore Biotherapeutics | not stated | Not stated |
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Mar 16, 2016 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT03276819 | A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML…(UMBRELLA) | N/A | terminated | Sep 8, 2017 | Centre Leon Berard | Early termination of the study, since July 31, 2020 for insufficient recruitment | Enrollment / accrual |
| NCT04146779 | Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-Radiation | N/A | terminated | Oct 31, 2019 | Vanderbilt-Ingram Cancer Center | COVID-19 | COVID-19 / pandemic |
| NCT03957096 | A Safety Study of SGN-CD47M in Patients With Solid Tumors | Phase 1 | terminated | May 21, 2019 | Seagen Inc. | Sponsor decision based on portfolio prioritization | Sponsor / business decision |
| NCT00603941 | A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel | Phase 1 / Phase 2 | terminated | Jan 29, 2008 | Daiichi Sankyo | Due to low enrollment, no participant had a dose limiting toxicity, therefore a maximum tolerated… | Safety / toxicity |
| NCT04058145 | AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck… | Phase 2 | withdrawn | Aug 15, 2019 | Massachusetts General Hospital | Funding Withdrawn | Funding |
| NCT04106843 | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Sep 27, 2019 | M.D. Anderson Cancer Center | No Participants Registered | Other (stated, no rule matched) |
| NCT04093115 | Study of CX1106 in Patients With Advanced Head and Neck Squamous Cell Carcinoma(HNSCC) | Phase 2 | withdrawn | Sep 17, 2019 | Beijing Konruns Pharmaceutical Co., Ltd. | The study was terminated voluntarily by the sponsor due to changes in clinical development strategy. | Sponsor / business decision |
| NCT02464137 | HYpofractionateD RadioAblative (HYDRA) Treatment of Advanced Laryngeal Cancer(HYDRA) | Phase 1 | terminated | Jun 8, 2015 | University of Texas Southwestern Medical Center | unexpected toxicities | Safety / toxicity |
| NCT04276454 | Lymphedema Treatment in Head and Neck Cancer Patients | N/A | withdrawn | Feb 19, 2020 | Endeavor Health | Per investigator's request. | Investigator |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors… | Phase 1 | terminated | Nov 29, 2010 | AIDS Malignancy Consortium | Inadequate accrual rate | Enrollment / accrual |
| NCT03714867 | Pre-Operative Pregabalin for Post-Operative Pain in Head and Neck Cancer Surgery | Phase 4 | withdrawn | Oct 22, 2018 | Augusta University | Inability to recruit patients | Enrollment / accrual |
| NCT02842125 | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda)… | Phase 1 / Phase 2 | terminated | Jul 22, 2016 | MultiVir, Inc. | Arm C rolled into parallel study; Arms A and B halted for greater efficacy in Arm C | Efficacy / futility |
| NCT00181220 | Valproic Acid in the Induction of EBV Lytic Cycle Antigen Expression in Nasopharyngeal… | Phase 1 | withdrawn | Sep 16, 2005 | Johns Hopkins University | PI left JHU and is not able to be reached for updates | Investigator |
| NCT00367718 | Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma | Phase 2 | withdrawn | Aug 23, 2006 | Johns Hopkins University | PI left JHU and is not able to be reached for updates | Investigator |
| NCT01192815 | Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the… | Phase 2 | terminated | Sep 1, 2010 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT01133678 | Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck | Phase 2 | terminated | May 31, 2010 | University of Chicago | Primary endpoint reached futility boundary | Efficacy / futility |
| NCT02236936 | Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the…(AGMT_HNO_PN) | Phase 3 | terminated | Sep 11, 2014 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Study stopped due to low recruitment | Enrollment / accrual |
| NCT01111058 | Everolimus Versus Placebo in Head and Neck Cancer | Phase 2 | terminated | Apr 27, 2010 | University of Chicago | Slow accrual | Enrollment / accrual |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and… | Phase 1 / Phase 2 | terminated | May 22, 2015 | Daiichi Sankyo | Terminated early for insufficient evidence of clinical efficacy | Efficacy / futility |
| NCT01265381 | Thyroid Cancer Among Chornobyl Clean-up Workers in Ukraine: Pilot Study | — | terminated | Dec 23, 2010 | National Cancer Institute (NCI) | This protocol was determined to be not human subjects research. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 31, 2021source: clinicaltrials